tiprankstipranks
Mesoblast Limited (AU:MSB)
ASX:MSB
Australian Market
MSB
Mesoblast Limited
RESEARCH TOOLSreports

Mesoblast Limited (MSB) Stock News & Sentiment

307 Followers
Mesoblast Outlines R&D Outlook and Flags Risks Around Stem Cell Pipeline
Premium
Company Announcements
Mesoblast Outlines R&D Outlook and Flags Risks Around Stem Cell Pipeline
1d ago
Mesoblast Targets Revenue Expansion and Pipeline Upside at Inaugural R&D Day
Premium
Company Announcements
Mesoblast Targets Revenue Expansion and Pipeline Upside at Inaugural R&D Day
1d ago
Mesoblast Wins FDA Nod for Registrational Ryoncil Trial in Duchenne Muscular Dystrophy
Premium
Company Announcements
Mesoblast Wins FDA Nod for Registrational Ryoncil Trial in Duchenne Muscular Dystrophy
2d ago
Mesoblast Seeks ASX Quotation for 1.26 Million New Shares
Premium
Company Announcements
Mesoblast Seeks ASX Quotation for 1.26 Million New Shares
2d ago
Mesoblast Plans New Share Issue to Raise Capital
Premium
Company Announcements
Mesoblast Plans New Share Issue to Raise Capital
3d ago
Mesoblast Earnings Call: Ryoncil Momentum, Pipeline Upside
Premium
Company Announcements
Mesoblast Earnings Call: Ryoncil Momentum, Pipeline Upside
14d ago
Mesoblast CEO Granted Additional Options Following Shareholder Approval
Premium
Company Announcements
Mesoblast CEO Granted Additional Options Following Shareholder Approval
21d ago
More AU:MSB News >

MSB News on the Web

Jefferies Reaffirms Their Buy Rating on Mesoblast Limited (MEOBF)
TipRanks News
Neutral
Lunch Wrap: ASX wobbles on shaky ceasefire, Bendigo surges as AI cuts jobs
StockHead
Neutral
Health Check: ‘We’ve only just started’, Mesoblast tells investors at inaugural show-and-tell
StockHead
Neutral
Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy
Simply Wall St
Neutral
Mesoblast receives IND clearance from FDA for Ryoncil trial
TipRanks News
Neutral
Mesoblast Outlines R&D Outlook and Flags Risks Around Stem Cell Pipeline
TipRanks News
Neutral
Mesoblast Wins FDA Nod for Registrational Ryoncil Trial in Duchenne Muscular Dystrophy
TipRanks News
Bullish
Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?
Simply Wall St
Neutral

News Score - Last 7 Days

Very Positive
AU:MSB
Sector Average
Media Buzz
This Week13 articles
Weekly Average6 articles
News Sentiment
This Week80%
Sector Average69%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is AU:MSB’s Media Buzz Sentiment?
13 articles about AU:MSB were published this week. In an average week, 6 articles are published.
    What is AU:MSB’s weekly average amount of articles?
    In an average week, 6 articles about AU:MSB are published.
      What is AU:MSB’s News Sentiment?
      80% of articles about AU:MSB were positive this week, compared to its sector average of 69%.
        Healthcare Stocks that are Trending in the News
        NBIXNeurocrine
        STAAStaar Surgical
        AORTArtivion
        OWLTOwlet
        HUMHumana
        Showing the stocks with the most bullish news sentiment over the past week